Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Recommendation of “Hold” from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned an average recommendation of “Hold” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $3.75.

Several brokerages recently issued reports on HOWL. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Wall Street Zen upgraded Werewolf Therapeutics to a “sell” rating in a research note on Saturday, August 1st.

Insider Buying and Selling at Werewolf Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total value of $145,918.85. Following the transaction, the insider owned 303,719 shares of the company’s stock, valued at approximately $106,301.65. The trade was a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Luke Evnin sold 107,429 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,513,385 shares of company stock worth $982,239 in the last three months. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter worth about $48,000. Regal Investment Advisors LLC lifted its position in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares during the last quarter. AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the first quarter valued at approximately $79,000. Finally, Susquehanna International Group LLP grew its holdings in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Down 3.8%

NASDAQ:HOWL opened at $0.38 on Tuesday. The business’s 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.59. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38. The stock has a market cap of $18.57 million, a PE ratio of -0.50 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. Sell-side analysts anticipate that Werewolf Therapeutics will post -1.08 earnings per share for the current fiscal year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.